Drug Profile
PF 5057459
Alternative Names: CovX 241; CVX-241; PF-05057459Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CovX
- Developer Pfizer
- Class Antibodies; Antineoplastics; Peptides
- Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 10 Nov 2011 Discontinued - Phase-I for Solid tumours in USA (IV)
- 14 Sep 2011 Pfizer terminates phase I trial in advanced Solid tumours in USA (NCT01004822)
- 01 Mar 2010 Phase-I clinical trials in Solid tumours in USA (IV)